'Peg rbv' presentation slideshows

Sofosbuvir ( Sovaldi )

Sofosbuvir ( Sovaldi ). Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: July 14, 2015. Sofosbuvir ( Sovaldi ). Background and Dosing. Sofosbuvir ( Sovaldi ). Approval Status : FDA approved December 6, 2013

2.02k views • 194 slides

Daclatasvir ( Daklinza )

Daclatasvir ( Daklinza ). Prepared by: H. Nina Kim, MD MSc and David Spach, MD Last Updated: March 10, 2017. Daclatasvir ( Daklinza ). Background Information. Daclatasvir ( Daklinza ). Approval Status : Approved by United States FDA July 24, 2015

1.09k views • 108 slides

Supported by:

Presented by. Jointly sponsored by the Duke University School of Medicine and The Chronic Liver Disease Foundation. Supported by:. Educational Objectives.

953 views • 85 slides

How to Optimize Treatment of non G1 Patients

Luncheons PHC Paris January 31, 2012. How to Optimize Treatment of non G1 Patients. Alessandra Mangia S. Giovanni Rotondo ITALY. March 14, 2011. 49 years old man, BMI: 28 HCV diagnosed in 1998 - previous iv drug and alcohol user - genotype 3, HCVRNA:410.000 IU/ml

503 views • 50 slides

Hepatitis-C and HIV

Hepatitis-C and HIV. Michael T. Wong, MD Assistant Professor of Medicine, Harvard Medical School Division of Infectious Diseases, Beth Israel Deaconess Medical Center. HCV Primarily through blood and blood products, IDU

618 views • 46 slides

Standard Interferon vs. Pegylated Interferon

311 views • 30 slides

Recent HCV treatment developments: In pursuit of perfectovir

594 views • 29 slides

?????????

???????????????. ?????????. ?????????. Frequent curability of diverse populations without IFN. IFN-free DAA combinations (GT1). Ribavirin. Suppression of HCV with DAA combination (PI + NI). Potential approval of other DAAs with IFN (eg, faldaprevir). Proof of concept for DAA (PI).

272 views • 26 slides

155 views • 15 slides

144 views • 14 slides

Simeprevir in Genotype 1 ( Viral Relapsers ) PROMISE Trial

Phase 3. Treatment Experienced. Simeprevir in Genotype 1 ( Viral Relapsers ) PROMISE Trial. Forns X , et al. Gastroenterology. 2014;146:1669-79.e3. Simeprevir + PEG + Ribavirin for Chronic HCV PROMISE Trial. Source: Forns X , et al. Gastroenterology. 2014;146:1669-79.e3.

135 views • 13 slides

92 views • 9 slides

Treatment of Chronic HCV Genotype 2 thru 6

326 views • 6 slides